Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 50 of 50 results for bortezomib

  1. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338)

    This guidance has been updated and replaced by NICE technology appraisal guidance 427.

    Technology appraisal guidance
    Published
    25 March 2015

  2. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

    Evidence summary
    Published
    26 June 2015

  3. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015

  4. Past appeals and decisions

    Past technology appraisal appeals and decisions

  5. NICE leads the way in approving breakthrough treatment for multiple myeloma

    People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.

    News
    Last updated
    13 June 2025